Table 1 Baseline characteristics of trial participants across obesity categoriesa

From: Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Characteristic

BMI <35 kg m−2 (n = 180)

BMI 35–<40 kg m−2 (n = 171)

BMI ≥40 kg m−2 (n = 178)

P value

Female, n (%)

91 (50.6)

88 (51.5)

118 (66.3)

0.0027

Age, years

72 (64, 78)

70 (63, 74)

67 (60, 73)

<0.0001

Ethnicity, n (%)b

   

0.8115

 Hispanic or Latino

13 (7.2)

9 (5.3)

14 (7.9)

 

 Not Hispanic or Latino

167 (92.8)

162 (94.7)

164 (92.1)

 

Race, n (%)b

   

0.1237

 Black/African American

10 (5.6)

2 (1.2)

9 (5.1)

 

 White

170 (94.4)

169 (98.8)

168 (94.4)

 

 Other

0 (0.0)

0 (0.0)

1 (0.6)

 

Body weight, kg

91.6 (84.1, 100.2)

105.8 (93.7, 117.5)

123.1 (110.0, 137.7)

<0.0001

BMI, kg m−2c

32.6 (31.3, 33.8)

37.1 (36.1, 38.4)

43.5 (41.3, 47.6)

d

Waist circumference, cm

110.0 (105.0, 116.8)

120.0 (113.0, 127.0)

129.0 (121.0, 141.0)

<0.0001

SBP, mmHg

132.0 (120.0, 141.5)

135.0 (122.0, 148.0)

132.0 (121.0, 140.0)

0.5912

NT-proBNP, pg ml−1

531.1 (278.7, 1083.8)

449.9 (205.5, 1058.8)

385.2 (181.0, 926.9)

0.0201

LVEF, %

56.0 (50.0, 60.0)

57.0 (50.0, 60.0)

58.0 (54.0, 61.0)

0.0206

LVEF stratification, n (%)

   

0.0928

 45–49%e

33 (18.3)

31 (18.1)

21 (11.8)

 

 ≥50%

147 (81.7)

140 (81.9)

157 (88.2)

 

KCCQ-CSS score

61.7 (46.9, 76.0)

60.9 (46.9, 72.9)

51.6 (34.9–65.6)

<0.0001

6MWD, m

351.0 (260.5, 402.5)

340.0 (261.3, 400.0)

272.0 (207.6, 347.8)

<0.0001

CRP, mg L−1

2.6 (1.5, 5.9)

3.8 (2.0, 7.4)

5.2 (2.8, 10.2)

<0.0001

HF hospitalization within 1 year, n (%)

32 (17.8)

20 (11.7)

29 (16.3)

0.6926

Comorbidities at screening, n (%)

 Atrial fibrillation

97 (53.9)

88 (51.5)

90 (50.6)

0.5283

 Hypertension

143 (79.4)

141 (82.5)

149 (83.7)

0.2950

 Coronary heart disease

80 (44.4)

51 (29.8)

49 (27.5)

0.0007

 Obstructive sleep apnea

24 (13.3)

15 (8.8)

27 (15.2)

0.6033

NYHA functional class, n (%)

   

0.0001

 Class II

136 (75.6)

119 (69.6)

95 (53.4)

 

 Class III

44 (24.4)

51 (29.8)

83 (46.6)

 

 Class IV

0 (0.0)

1 (0.6)

0 (0.0)

 

Concomitant medications, n (%)

 Diuretics

143 (79.4)

137 (80.1)

147 (82.6)

0.4520

 Loop diuretics

109 (60.6)

95 (55.6)

125 (70.2)

0.0602

 Loop diuretic dose (mg)f

40 (20, 40)

40 (20, 40)

40 (40, 80)

0.0002

 Thiazides

33 (18.3)

31 (18.1)

26 (14.6)

0.3489

 MRAs

56 (31.1)

58 (33.9)

70 (39.3)

0.1029

 ACE/ARB (ARNI)

129 (71.7)

132 (77.2)

136 (76.4)

0.2992

 ARNI

11 (6.1)

9 (5.3)

7 (3.9)

0.3492

 Beta-blockers

150 (83.3)

132 (77.2)

136 (76.4)

0.1070

 SGLT2i

10 (5.6)

7 (4.1)

2 (1.1)

0.0243

  1. Percentages may not equal 100% due to rounding.
  2. Two-sided P values for continuous variables are from a Jonckheere–Terpstra trend test, for binary variables from a Cochran–Armitage trend test and for multinomial variables from a Cochran–Mantel–Haenszel test.
  3. aData are median (Q1, Q3) unless otherwise stated and are from the full analysis set.
  4. bRace and ethnic group were reported by the investigator.
  5. cBMI is the weight in kilograms divided by the square of the height in meters.
  6. dNot relevant.
  7. eIncludes one participant with LVEF of 33%.
  8. fReported in furosemide equivalents per day.
  9. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; Q, quartile; SGLT2i, sodium-glucose co-transporter-2 inhibitor.
Back to article page